Characterization of LC-HCC fusion protein of Botulinum neurotoxin type a

Protein and Peptide Letters

Volumn 18, Issue 3, 2011, Pages 295-304

  Singh, Manglesh Kumar ^a   Dhaked, Ram Kumar ^a   Singh, Padma ^a   Gupta, Pallavi ^a   Singh, Lokendra ^a,b  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

^b Defence R D Organization   (India)

Author keywords

BoNT A; endopeptidase; ganglioside; LC HCC subunit; synaptic vesicles

Indexed keywords

BACTERIA (MICROORGANISMS); CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; RATTUS;

BOTULINUM TOXIN A; GANGLIOSIDE; HYBRID PROTEIN; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; CLOSTRIDIUM BOTULINUM; ENZYME ACTIVE SITE; ENZYMOLOGY; ESCHERICHIA COLI; FEMALE; GENE VECTOR; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; RAT; SERODIAGNOSIS; SYNAPSE VESICLE;

AMINO ACID SEQUENCE; ANIMALS; BOTULINUM TOXINS, TYPE A; CATALYTIC DOMAIN; CLONING, MOLECULAR; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; FEMALE; GANGLIOSIDES; GENETIC VECTORS; IMMUNIZATION; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; RATS; RECOMBINANT FUSION PROTEINS; SYNAPTIC VESICLES;

EID: 79955366253     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986611794578314     Document Type: Article

References (57)

1. Gill, D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev., 1982, 46, 86-94. (Pubitemid 12101491)
2. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev., 2000, 80, 717-766. (Pubitemid 30164948)
3. Ashford, D.A.; Kaiser, R.M.; Bales, M.E.; Shutt, K.; Patrawalla, A.; McShan, A.; Tappero, J.W.; Perkins, B.A.; Dannenberg, A.L. Planning against biological terrorism: lessons from outbreak investigations. Emerg. Infect. Dis., 2003, 9 (5), 515-519. (Pubitemid 36529507)
4. Kennedy, D. Beauty and the Beast. Science, 2002, 295 (5560), 1601. (Pubitemid 34202865)
5. Wein, L.M.; Liu, Y. Analyzing a bioterror attack on the food sup- ply: the case of botulinum toxin in milk. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 9984-9989. (Pubitemid 40993679)
6. Johnson, E.A. Bacterial Pathogens and Toxins in Foodborne Dis- ease. In Food Safety: Contaminants and Toxins; D'Mello, J.P.F., Ed.; CAB International: Oxfordshire, U.K., 2003, pp. 25.
7. Schantz, E. J.; Johnson, E. A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev., 1992, 56, 80-99.
8. Smith, T.J.; Lou, J.; Geren, I.N.; Forsyth, C.M.; Tsai, R.; Laporte, S.L.; Tepp, W.H.; Bradshaw, M.; Johnson, E.A.; Smith, L.A.; Marks. J.D. Sequence variation within botulinum neurotoxin sero-types impacts antibody binding and neutralization. Infect. Immun., 2005, 73, 5450-5457. (Pubitemid 41192979)
9. Poulain, B.; Poppoff, M.R.; Molgo, J. How do the botulinum neu- rotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J., 2008, 1, 14-87.
10. Simpson, L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 167-193. (Pubitemid 38263838)
11. Singh, B.R. Intimate details of the most poisonous poison. Nat. Struct. Biol., 2000, 7, 617-619. (Pubitemid 30636667)
12. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol., 1998, 5, 898-902. (Pubitemid 28467413)
13. Kitamura M.; Takamiya, K.; Aizawa, S.; Furukawa, K.; Furukawa, K. Gangliosides are the binding substances in neural cells for teta- nus and botulinum toxins in mice. Biochim. Biophys. Acta, 1999, 1441, 1-3. (Pubitemid 29469431)
14. Kozaki, S.; Kamata, Y.; Watarai, S.; Nishiki, T.; Mochida, S. Gan-glioside GT1b as a complementary receptor component for Clos-tridium botulinum neurotoxins. Microb. Pathog., 1998, 25, 91-99. (Pubitemid 28398979)
15. Li, L.; Singh, B.R. Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. J. Nat. Toxins, 1998, 7, 215-226. (Pubitemid 28456458)
16. Ginalski, K.; Venclovas, C.; Lesyng, B.; Fidelis, K. Structure-based sequence alignment for the beta-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. FEBS Lett., 2000, 482, 119-124.
17. Binz, T.; Kurazono, H.; Wille, M.; Frevert, J.; Wernars, K.; Neimann, H. The complete sequence of botulinum neurotoxin type A and comparison with other Clostridial neurotoxins. J. Biol. Chem., 1990, 265, 9153-9158.
18. Emsley, P.; Fotinou, C.; Black, I.; Fairweather, N.F.; Charles, I.G.; Watts, C.; Hewitt, E.; Isaacs, N.W. The structures of the H(C) fragment of tetanus toxin with carbohydrate subunit complexes provide insight into ganglioside binding. J. Biol. Chem., 2000, 275, 8889-8894. (Pubitemid 30180245)
19. Byrne, M.P.; Smith L.A. Development of vaccines for prevention of botulism. Biochimie, 2000, 82, 955-966.
20. Smith, L.A. Development of recombinant vaccines for botulinum neurotoxin. Toxicon, 1998, 36, 1539-1548. (Pubitemid 28511068)
21. Byrne, M.P.; Smith, T.J.; Montgomery, V.A.; Smith, L.A. Purification, potency, and efficacy of the recombinant vaccine candidate botulinum neurotoxin type A binding domain from Pichia pastoris. Infect. Immun., 1998, 66, 4817-4822. (Pubitemid 28453087)
22. Potter, K.A.; Zhang, W.; Smith, L.A.; Meagher, M.M. Production and purification of the heavy chain fragment C of botulinum neuro-toxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr. Purif., 2000, 19, 393-402.
23. Smith, L.A.; Jensen, M.J.; Montgomery, V.A.; Brown, D.R.; Ahmed, S.A.; Smith, T.J.; Roads from vaccines to therapies. Mov. Di-sord., 2004, 19, S48-52 [24] (Pubitemid 38967511)
24. Zhang, W.; Smith, L.A.; Plantz, B.A.; Schlegel, V.L.; Meagher, M.M. Design of methanol feed control in Pichia pastoris fermentations based upon a growth model. Biotechnol. Prog., 2002, 6, 1392-1399. (Pubitemid 35450899)
25. Boles, J.; West, M.; Montgomery, V.; Tammariello, R.; Pitt, M.L.; Gibbs, P.; Smith, L.; LeClaire, R.D. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (Hc)) immune response and protection in the rhesus monkey. Toxicon, 2006, 47, 877-884 (Pubitemid 43849892)
26. Potter, K.J.; Bevins, M.A.; Vassilieva, E.V.; Chiruvolu, V.R.; Smith, T.J.; Smith, L.A.; Meagher, M.M. Production and purification of the heavy chain fragment C of botulinum neurotoxin, sero-type B, expressed in the methylotropic yeast Pichia pastoris. Protein Expr. Purif ., 1998, 13, 357-365. (Pubitemid 28378829)
27. Webb, R.P.; Smith, T.J.; Wright, P.M.; Montgomery, V.A.; Meagher, M.M.; Smith, L.A. Protection with recombinant Clostrid-ium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine, 2007, 25, 4273-4282. (Pubitemid 46635938)
28. Dux, M.P.; Barent, R.; Sinha, J.; Gouthro, M.; Swanson, T.; Bar-thuli, A.; Inan, M.; Ross, J.T.; Smith, L.A.; Smith, T.J.; Webb, R.; Loveless, B.; Henderson, I.; Meagher, M.M. Purification and scale-up of a recombinant heavy chain fragment C of botulinum neuro-toxin serotype E in Pichia pastoris. Protein Expr. Purif., 2006, 45, 359-367. (Pubitemid 43120441)
29. Loveless, B.M. Clostridium botulinum neurotoxin type E binding domain from Pichia pastoris as a recombinant vaccine candidate. Master of Science Thesis. Frederick, MD: Hood College, 2001.
30. Byrne, M.P.; Titball, R.W.; Holley, J.; Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin serotype F from Pichia pastoris. Protein Expr. Purif., 2000, 18, 327-337. (Pubitemid 30213451)
31. Johnson, S.K.; Zhang, W.; Smith, L.A.; Potter, K.J.; Swanson, S.T.; Schlegel, V.L.; Meagher, M.M. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris. Protein Expr. Purif., 2003, 32, 1-9. (Pubitemid 37436130)
32. Tavallaie, M.; Chenal, A.; Gillet, D.; Pereira, Y.; Manuch, M.; Gibert, M.; Raffestin, S.; Popoff, M.R.; Marvaud, J.C. Interaction between the two subdomains of the C-terminal part of the botu- linum neurotoxin A is essential for the generation of protective antibodies. FEBS. Lett., 2004, 572, 299-306. (Pubitemid 39092553)
33. Gilsdorf, J.; Gul, N.; Smith, L.A. Expression, purification, and characterization of Clostridium botulinum type B light chain. Protein Expr. Purif., 2006, 46, 256-267.
34. Jensen, M.J.; Smith, T.J.; Ahmed, S.A.; Smith, L.A. Expression, purification, and efficacy of type A botulinum neurotoxin catalytic domain fused to two translocation domain variants. Toxicon, 2003, 41, 691-701. (Pubitemid 36515008)
35. Kiyatkin, N.; Maksymowych, A.B.; Simpson, L.L. Induction of an immune response by an oral administration of recombinant botu-linum toxin. Infect. Immun., 1997, 65, 4586-4591. (Pubitemid 27463229)
36. Takahashi, T.; Joshi, S.G.; Al-Saleem, F.; Ancharski, D.; Singh, A.; Nasser, Z.; Simpson, L.L. Localization of the sites and characterization of the mechanism by which anti-light chain antibodies neutralize the actions of the botulinum holotoxin. Vaccine, 2009, 27, 2616-2624.
37. Webb, R.P.; Smith, T.J.; Wright, P.; Brown, J.; Smith, L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine, 2009, 27, 4490-4497.
38. Smith, L.A.; Byrne, M. Vaccines for preventing botulism. In: Brin, M.; Jankovic, J.; Hallett, M., Eds. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkens; 2002; pp. 427-440.
39. Chaddock, J.A.; Herbert, M.H.; Ling, R.J; Alexander, F.C.G.; Fooks, S.J.; Revell, D.F.; Quinn, C.P.; Shone, C.C.; Foster K.A. Expression and purification of catalytically active, non-toxic en-dopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif., 2002, 25, 219-228. (Pubitemid 35307504)
40. Shone, C.; Agostini, H.; Clancy, J.; Gu, M.; Yang, H.H.; Chu, Y.; Johnson, V.; Taal, M.; McGlashan, J.; Brehm, J.; Tong. X. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect. Immun., 2009, 77, 2795-2801.
41. Benfenati, F.; Bahler, M.; Jahn, R.; Greengard, P. Interactions of synapsin I with small synaptic vesicles: distinct sites in synapsin I bind to vesicle phospholipids and vesicle proteins. J. Cell. Biol., 1989, 108, 1863-1872. (Pubitemid 19130519)
42. Chou, J.H.; Jahn, R. Binding of Rab 3A to synaptic vesicles. J. Biol. Chem. 2000, 275, 9433-9440.
43. Walsh-Solimena, C.; Blasi, J.; Edelmann, L.; Chapman, E.R.; von Mollard, G.F.; Jahn, R. The t-SNARE syntaxin 1 and SNAP-25 are present on organelles that participate in synaptic vesicle recycling. J. Cell Biol., 1995, 128, 637-645.
44. Ferracci, G.; Seagar, M.; Joël, C.; Miquelis, R.; Lévêque C. Real time analysis of intact organelles using surface plasmon resonance. Analyt. Biochem., 2004, 334, 367-375. (Pubitemid 39370971)
45. Zhou, Y.; Singh, B.R. Cloning, high level expression, single step purification and binding activity of His6-tagged recombinant type B Botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr. Purif., 2004, 34, 8-16. (Pubitemid 38272309)
46. Cai, S.; Sarkar, H.K.; Singh, B.R. Enhancement of the Endopepti-dase Activity of Botulinum Neurotoxin by Its Associated Proteins and Dithiothreitol. Biochemistry, 1999, 38, 6903-6910.
47. Clayton, M.A.; Clayton, J.M.; Brown, D.R.; Middlebrook, J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun., 1996, 63, 2738-2742.
48. Lacy, D.B.; Stevens, R.C. Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expr. Purif., 1997, 11, 195-200. (Pubitemid 27498908)
49. Li, L.; Singh, B.R. In Vitro translation of type A Clostridium botu-linum neurotoxin heavy chain and analysis of its binding to rat syn-aptosomes. J. Protein Chem., 1999, 18, 89-95. (Pubitemid 29117429)
50. Kadkhodayan, S.; Knapp, M.S.; Schmidt, J.J.; Fabes, S.E.; Rupp, B.; Balhorn, R. Cloning, expression, and one-step purification of the minimal essential domain of the light chain of botulinum neuro-toxin type A. Protein Expr. Purif., 2000, 19, 125-130. (Pubitemid 30387903)
51. Montecucco, C. How do tetanus and botulinum toxins bind to neu-ronal membranes? Trends Biochem. Sci., 1986, 11, 315-317.
52. Montecucco, C.; Rossetto, O.; Schiavo, G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol., 2004, 12, 442-446. (Pubitemid 39286121)
53. Kitamura, M.; Iwamori, M.; Nagai, Y. Interaction between Clostri-dium botulinum neurotoxin and gangliosides. Biochim. Biophys. Acta, 1980, 628, 328-335. (Pubitemid 10119130)
54. Rummel, A.; Mahrhold, S.; Bigalke, H.; Binz, T. The Hcc-domain of botulinum neurotoxins A and B exhibits a singular gangliosside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol., 2004, 51, 631-643. (Pubitemid 38233933)
55. Simpson, L.L.; Rapport, M.M. Ganglioside inactivation of botu-linum toxin. J. Neurochem., 1971, 18, 1341-1343.
56. Yowler, B.C.; Schengrund, C.L. Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry, 2004, 43, 9725-9731. (Pubitemid 38993822)
57. Yowler, B.C.; Kensinger, RD.; Schengrund, C.L. Botulinum neuro-toxin A activity is dependent upon the presence of specific ganglio-sides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem., 2002, 277, 32815-32819. (Pubitemid 34984791)